A method for preventing or treating renal disorder, disease, and/or injury includes administering to the subject and/or kidney a therapeutically effective amount of a 15-PGDH inhibitor.

The present invention relates to an emulsion composition for chemoembolization comprising a nanoparticle comprising a drug and a biocompatible polymer, a water-soluble contrast agent and a water-insoluble contrast agent, and a water-insoluble drug as well as an aqueous drug can be administered in a form of stable emulsion, and drugs are slowly released, thereby enhancing the effect of chemoembolization.

The liquid vehicles can be used to create dilute solutions of water-soluble pharmaceutical or non-pharmaceutical oral contrast agents. The liquid vehicles are formulated to provide desired osmolalities, viscosities, pH, and taste masking capabilities to match the particular intentions of the user and to complement the inherent differences in the various oral contrast agents. The liquid vehicles comprise an aqueous medium, an osmotic agent to adjust osmolality, a buffering agent, a viscosity agent, and sweeteners and flavoring agents to improve palatability.

The invention relates to a system and a method for determining a characteristic of a blood vessel portion, which comprises blood including a contrast agent exhibiting resonant absorption of x-ray photons at a specific energy. The system comprises a tunable monochromatic x-ray source (21) emitting x-ray radiation, an x-ray detector device (22) for detecting the x-ray radiation after it has travelled through the blood vessel portion. A control unit (26) varies a tuning of the x-ray source (21) to vary the energy of the x-ray radiation emitted by the x-ray source (21), and an evaluation unit (27) determines a tuning of the x-ray source (21) at which nuclear resonant absorption of the x-ray radiation incident onto the blood vessel portion occurs and estimates the characteristic on the basis of the determined tuning. The characteristic may particularly be the blood velocity in the blood vessel portion.

The present invention relates to injectable, thermosensitive hydrogel compositions comprising linezolid for relieving and/or treating chronic low back pain (CLBP).

The liquid vehicles can be used to create dilute solutions of water-soluble pharmaceutical or non-pharmaceutical oral contrast agents. The liquid vehicles are formulated to provide desired osmolalities, viscosities, pH, and taste masking capabilities to match the particular intentions of the user and to complement the inherent differences in the various oral contrast agents. The liquid vehicles comprise an aqueous medium, an osmotic agent to adjust osmolality, a buffering agent, a viscosity agent, and sweeteners and flavoring agents to improve palatability.

The present invention relates to a composition comprising non-water soluble dissacharides and oil, a solvent and at least one pharmaceutical ingredient, wherein the composition contains at least two compounds selected from saccharides and lipid oils such as lactose octabenzoate Methyl hepta-O-isobutyryl-α,β-lactoside, α,β-Lactose octa para-iodobenzoate, 3-iodobenzyl hepta-O-isobutyryl-α,β-lactoside, lactose octapropionate, lactose octaisobutyrate, sucrose octabenzoate, glycerol trihexanoate, Glycerol trioctanoate, Glycerol tridecanoate, Lipiodol, ethyl myristate, ethyl palmitate, ethyl oleoate and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 2,000 centipoise (cP) after administration.

Proposed are a contrast agent containing an iodinated unsaturated fatty acid ethyl ester derived from vegetable oil, a non-iodinated unsaturated fatty acid ethyl ester, and sulfur dioxide (SO.sub.2), and a production method thereof. The contrast agent having a similar contrast effect is synthesized using vegetable oil as a substitute for poppy seed oil, which is unstable in terms of supply and is expensive. In addition, the long-term stability problem of an iodine-based contrast agent is solved by adding a non-iodinated unsaturated fatty acid ethyl ester and sulfur dioxide.

The presently-disclosed subject matter relates to adsorptive radiocontrast constructs in multiple advantageous structural embodiments, which are designed to possess dual therapeutic and diagnostic actions. A concomitant therapeutic antiplatelet, as well as vasodilatation, effects, and a diagnostic real-time continuous visualization of an artery, can be obtained via direct injection of the constructs into said artery using a suitable catheter during procedural angiography with or without percutaneous intervention.

An iodinated CT contrast agent made of fatty acid derivatives for non-invasive visualisation and quantification of the brown and/or beige adipose tissue (BAT) or for imaging the heart and/or liver of a subject, to be taken orally which is a breakthrough in CT imaging. Image resolution by CT is significantly enhanced compared to PET.